Ayala is a clinical stage precision oncology company dedicated to developing targeted therapies for genomically defined, clinically underserved cancers.

We look to target rare and unique cancers, in which the Notch pathway has been implicated. Notch is a proven oncogenic driver in defined cancers. Our focus is inhibiting the Notch pathway with potentially best in class gamma secretase inhibitors (GSIs).

We aim to match the right patient to the right drug, and hope to achieve the promise of precision oncology: deliver better clinical outcomes and greater benefits for patients, caregivers and healthcare providers.

In 2017, we entered into an exclusive worldwide license agreement with Bristol-Myers Squibb for their GSIs for the potential treatment of cancers.

Our lead product, AL101, has completed preclinical and phase 1 studies. A phase 2 study (ACCURACY) for AL101 in patients with adenoid cystic carcinoma (ACC) bearing Notch activating mutations is ongoing. Additional two Phase 2 studies are planned in patients with tumors bearing Notch activating mutations in Triple Negative Breast Cancer (TNBC) and in T-cell Acute Lymphoblastic Leukemia (T-ALL).

In 2018, we entered a deal with Novartis to develop and commercialize AL102 in combination with BCMA-targeting agents in multiple myeloma. In addition, Ayala is evaluating AL102 as an inhibitor of the Notch pathway in additional indications.

Learn about our Notch pipeline
AL101 clinical trial

Our mission

At Ayala, we are focused on developing best in class targeted therapies for cancer patients with cancer in which the Notch pathway is activated. We target genomically-defined, clinically underserved cancers where we can have the most impact.

We are guided by strongly held values:


Improve outcomes in patients with underserved cancers


Be compassionate to the patients we serve


To consistently be open, honest, and ethical in all our endeavors


To efficiently bring innovative products to market for the benefit of our patients and shareholders

Our people